Press release
Acute Bacterial Skin and Skin Structure Infections Market to see upward surge in Future Scope
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) are the type of skin and soft tissue infections that affects the epidermis, dermis, and subcutaneous tissues. The US FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Pathogens such as Methicillin sensitive Staphylococcus aureus (MSSA), Methicillin resistant Staphylococcus aureus (MRSA), Beta-hemolytic Streptococcus, Escherichia coli, Enterococcus faecalis, and Pseudomonas aeruginosa are the major causes of ABSSSI.Request Here Sample Report:
https://www.coherentmarketinsights.com/insight/request-sample/1531
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations.
Moreover, in 2018, Fresenius Kabi received US FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.
Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to article published in 2015 of PLoS One journal, skin and skin structure infections related hospital admissions were 1.6% in 2005, increased to 2.0% in 2011.
Moreover, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.
๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐จ๐๐๐๐ซ!!! ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐ญ๐ก๐ ๐ซ๐๐ฉ๐จ๐ซ๐ญ ๐๐ญ ๐ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ๐๐ ๐ซ๐๐ญ๐!!!
๐ ๐ฅ๐๐ญ ๐๐ง๐ฌ๐ญ๐๐ง๐ญ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ ๐จ๐ ๐๐$ ๐๐๐๐
๐๐ฎ๐ฒ ๐๐ก๐ข๐ฌ ๐๐จ๐ฆ๐ฉ๐ฅ๐๐ญ๐ ๐ ๐๐ฎ๐ฌ๐ข๐ง๐๐ฌ๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.coherentMarketinsights.com/promo/buynow/1531
Major Market Competitors: Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Allergan plc, Merck & Co., Inc., Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Ltd.), Fresenius SE & Co. KGaA, Sandoz Inc. (a subsidiary of Novartis), Glenmark Pharmaceuticals Ltd, Cadila Healthcare Ltd., and Teva Pharmaceutical Industries Ltd.
๐ ๐ซ๐๐ช๐ฎ๐๐ง๐ญ๐ฅ๐ฒ ๐๐ฌ๐ค๐๐ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง๐ฌ?
๐๐ก๐๐ญ ๐ฐ๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ฌ๐ข๐ณ๐ ๐๐ ๐ข๐ง ๐๐๐๐?
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐๐๐๐ญ๐จ๐ซ๐ฌ ๐๐ซ๐ข๐ฏ๐ข๐ง๐ ๐ญ๐ก๐ ๐๐ฎ๐ซ๐จ๐ฉ๐๐๐ง ๐ฆ๐๐ซ๐ค๐๐ญ?
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐๐ก๐๐ฅ๐ฅ๐๐ง๐ ๐๐ฌ ๐ญ๐จ ๐ฆ๐๐ซ๐ค๐๐ญ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก?
๐๐ก๐จ ๐๐ซ๐ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ?
๐๐ก๐๐ญ ๐๐ซ๐ ๐ญ๐ก๐ ๐ฆ๐๐ซ๐ค๐๐ญ ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐๐ง๐ ๐ญ๐ก๐ซ๐๐๐ญ๐ฌ ๐๐๐๐๐ ๐๐ฒ ๐ญ๐ก๐ ๐ค๐๐ฒ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ?
๐๐ก๐๐ญ ๐ฐ๐ข๐ฅ๐ฅ ๐๐ ๐ญ๐ก๐ ๐ ๐ซ๐จ๐ฐ๐ญ๐ก ๐ซ๐๐ญ๐ ๐ข๐ง ๐๐๐๐?
๐๐ก๐ข๐๐ก ๐ฌ๐ญ๐ซ๐๐ญ๐๐ ๐ข๐๐ฌ ๐๐ซ๐ ๐ฎ๐ฌ๐๐ ๐๐ฒ ๐ญ๐จ๐ฉ ๐ฉ๐ฅ๐๐ฒ๐๐ซ๐ฌ ๐ข๐ง ๐ญ๐ก๐ ๐๐ค๐ค ๐๐๐ซ๐ค๐๐ญ?
Download PDF Brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1531
Contact us:
Mr. Shah
Senior Client Partner โ Business Development
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
sales@coherentMarketinsights.com
๐๐ฏ๐ผ๐๐ ๐๐ผ๐ต๐ฒ๐ฟ๐ฒ๐ป๐ ๐ ๐ฎ๐ฟ๐ธ๐ฒ๐ ๐๐ป๐๐ถ๐ด๐ต๐๐:-
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunities.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Acute Bacterial Skin and Skin Structure Infections Market to see upward surge in Future Scope here
News-ID: 2344539 • Views: โฆ
More Releases from Coherent Market Insights
Butylated Hydroxytoluene Market Forecast Through 2033 Highlights Emerging Trends โฆ
The global butylated hydroxytoluene market size is valued at US$ 237.1 Million in 2025 and is expected to reach US$ 346.9 Million by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032.
The latest report by Coherent Market Insights indicates strong growth potential for the Butylated Hydroxytoluene Market from 2026 to 2033, supported by rising industry demand, expanding applications, and ongoing technological advancements. The studyโฆ
Metal Organic Framework Market Set to Witness Significant Growth by 2025-2032 | โฆ
Metal Organic Framework Market is estimated to be valued at USD 39.89 Mn in 2025 and is expected to reach USD 136.4 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 19.2% from 2025 to 2032.
The Global Business Landscape is being reshaped by rapid innovation, rising investment and shifting regional dynamics - and at the heart of this transformation lies the Metal Organic Framework Market. From 2026 toโฆ
Nickel Metal Hydride Battery Market is Going to Boom |Panasonic Industry Co., Lt โฆ
The Nickel Metal Hydride Battery Market is estimated to be valued at USD 3,402.1 Mn in 2025 and is expected to reach USD 4,118.1 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 2.8% from 2025 to 2032.
The latest report by Coherent Market Insights indicates strong growth potential for the Nickel Metal Hydride Battery Market from 2026 to 2033, supported by rising industry demand, expanding applications, and ongoingโฆ
Custom Shoes Market to Witness Stunning Growth 2026-2033 With Nike, Adidas, New โฆ
The custom shoes Market size was valued at US$ 6.65 Bn in 2025 and is expected to reach US$ 14.7 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.0% from 2025 to 2032.
The Global Business Landscape is being reshaped by rapid innovation, rising investment and shifting regional dynamics - and at the heart of this transformation lies the Custom Shoes Market. From 2026 to 2033, thisโฆ
More Releases for ABSSSI
ABSSSI Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Lands โฆ
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Bacterial Skin and Skin-Structure Infection pipeline constitutes 2+ key companies continuously working towards developing 2+ Acute Bacterial Skin and Skin-Structure Infection treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Acute Bacterial Skin and Skin-Structure Infection Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinicalโฆ
Revolutionizing Care: Breakthroughs Propel the ABSSSI Treatment Market into a Ne โฆ
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) represent a significant clinical and economic burden worldwide, affecting patients across outpatient clinics, hospitals, and long-term care facilities. From simple cellulitis to complex wound infections, these conditions require prompt, effective therapy to prevent serious complications and reduce healthcare costs. Today, the ABSSSI treatment market is undergoing a renaissance, driven by novel antibiotic classes, innovative delivery systems, and a heightened focus on antimicrobialโฆ
ABSSSI Therapeutics Market Size in the 7MM is anticipated to increase by 2034 an โฆ
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Acute Bacterial Skin and Skin Structure Infections, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin Structure Infections market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock key insights into the ABSSSI Market! Downloadโฆ
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI) Treatment Market Size โฆ
Acute Bacterial Skin and Skin Structure Infections Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Acute Bacterial Skin and Skin Structure Infections Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Acute Bacterial Skin and Skin Structure Infections Market Insights, Epidemiology andโฆ
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market โ Detailed โฆ
Acute Bacterial Skin and Skin Structure Infections Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities and application landscape of the Acute Bacterial Skin and Skin Structure Infections depending on the industry's financial and non-financial impact. The complete range of informationโฆ
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Rapidly Devel โฆ
The major market driver for growth of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received US FDA for its product Baxdela, a delafloxacin basedโฆ
